E. A. Copelan

747 total citations
15 papers, 564 citations indexed

About

E. A. Copelan is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, E. A. Copelan has authored 15 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 4 papers in Oncology and 4 papers in Genetics. Recurrent topics in E. A. Copelan's work include Hematopoietic Stem Cell Transplantation (4 papers), Virus-based gene therapy research (3 papers) and Mesenchymal stem cell research (2 papers). E. A. Copelan is often cited by papers focused on Hematopoietic Stem Cell Transplantation (4 papers), Virus-based gene therapy research (3 papers) and Mesenchymal stem cell research (2 papers). E. A. Copelan collaborates with scholars based in United States. E. A. Copelan's co-authors include P. J. Tutschka, Patricia L. Strohm, M. S. Kennedy, Jong‐Dae Lee, L M Rogers, Pappachan E. Kolattukudy, Peter D. Zimmerman, Bernd Stein, Lawrence E. Mathes and Mark G. Lewis and has published in prestigious journals such as The Journal of Immunology, Infection and Immunity and Stem Cells.

In The Last Decade

E. A. Copelan

15 papers receiving 532 citations

Peers

E. A. Copelan
Comparison fields: 5 of 78
  • Immunology 215
  • Hematology 165
  • Infectious Diseases 109
  • Epidemiology 86
  • Molecular Biology 83
Martial Lacroix Canada
Debra D. Hiraki United States
Inmaculada Esparza United States
Andres Männik Estonia
J W Mannhalter Austria
Andrea Matucci Italy
G. Schumann Switzerland
Abdelhakim Ben Nasr United States
Kedarnath N. Sastry United States
Y. Guédez Venezuela
Martial Lacroix Canada View profile →
Citations per field, relative to E. A. Copelan
E. A. Copelan · 1×
Citations per year, relative to E. A. Copelan
E. A. Copelan · 1×

Countries citing papers authored by E. A. Copelan

Since Specialization
Citations

This map shows the geographic impact of E. A. Copelan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. A. Copelan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. A. Copelan more than expected).

Fields of papers citing papers by E. A. Copelan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. A. Copelan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. A. Copelan. The network helps show where E. A. Copelan may publish in the future.

Co-authorship network of co-authors of E. A. Copelan

This figure shows the co-authorship network connecting the top 25 collaborators of E. A. Copelan. A scholar is included among the top collaborators of E. A. Copelan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. A. Copelan. E. A. Copelan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
# Title Journal Authors Indexed citations
1 High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma Leukemia Research Don M. Benson, Patrick Elder et al. 24
2 Creation of a research database to comply with the HIPPA Privacy Act Biology of Blood and Marrow Transplantation E. A. Copelan, Patrick Elder et al. 1
3 NCCN Practice Guidelines for Chronic Myelogenous Leukemia. PubMed Ellin Berman, R A Clift et al. 1
4 Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. PubMed Firoozeh Sahebi, E. A. Copelan et al. 10
5 Use of the Ohio state busulfan/cyclophasphamide regimen in recipients of matched unrelated donor transplants Bone Marrow Transplantation J. Gajewski, Firoozeh Sahebi et al. 1
6 HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation. PubMed C Keever, Isabel Cunningham et al. 89
7 Controlled trial of orally administered immunoglobulin following bone marrow transplantation. PubMed E. A. Copelan, John P. Klein et al. 11
8 Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). PubMed E. A. Copelan, J. C. Biggs et al. 20
9 Evidence for possible involvement of an elastolytic serine protease in aspergillosis Infection and Immunity Pappachan E. Kolattukudy, Jong‐Dae Lee et al. 165
10 Lymphocytotoxic strains of feline leukemia virus induce apoptosis in feline T4-thymic lymphoma cells. PubMed J. L. Rojko, Richard M. Fulton et al. 43
11 Purine Metabolism in Feline Lymphomas Veterinary Pathology E. A. Copelan, Susan Johnson et al. 2
12 Hemolysis following intravenous immune globulin therapy Transfusion E. A. Copelan, Patricia L. Strohm et al. 92
13 Experience with sandoglobulin in bone marrow transplantation Stem Cells P. J. Tutschka, E. A. Copelan 3
14 A comparison of the effects of mezlocillin and carbenicillin on haemostasis in volunteers Journal of Antimicrobial Chemotherapy E. A. Copelan, Laura C. Miller et al. 13
15 The mechanism of retrovirus suppression of human T cell proliferation in vitro. The Journal of Immunology E. A. Copelan, J. J. Rinehart et al. 89

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026